Ilishaan Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-07-2024
- Paid Up Capital ₹ 0.10 M
as on 17-07-2024
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 M
as on 17-07-2024
- Revenue -73.64%
(FY 2023)
- Profit -67.04%
(FY 2023)
- Ebitda -14.46%
(FY 2023)
- Net Worth -89.20%
(FY 2023)
- Total Assets -9.35%
(FY 2023)
About Ilishaan Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M.
Jaya Bhandari and Ashish Bhandari serve as directors at the Company.
- CIN/LLPIN
U24233MP2013PTC030450
- Company No.
030450
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ilishaan Biotech Private Limited offer?
Ilishaan Biotech Private Limited offers a wide range of products and services, including Food Ingredients, Rapid Test Kit, Elisa Kits.
Who are the key members and board of directors at Ilishaan Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaya Bhandari  | Director | 03-Apr-2013 | Current |
| Ashish Bhandari | Director | 03-Apr-2013 | Current |
Financial Performance of Ilishaan Biotech.
Ilishaan Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 73.64% decrease. The company also saw a substantial fall in profitability, with a 67.04% decrease in profit. The company's net worth observed a substantial decline by a decrease of 89.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ilishaan Biotech?
In 2023, Ilishaan Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adinath Veterinary Products Private LimitedActive 12 years 9 monthsAshish Bhandari is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 07 Oct 2020 | ₹5.00 M | Open |
How Many Employees Work at Ilishaan Biotech?
Unlock and access historical data on people associated with Ilishaan Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ilishaan Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ilishaan Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
